Status:
ACTIVE_NOT_RECRUITING
Discontinuation of Antiviral Therapy as a Strategy to Cure Hepatitis B
Lead Sponsor:
Göteborg University
Collaborating Sponsors:
Sahlgrenska University Hospital
Conditions:
Hepatitis B, Chronic
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Cirrhosis or cancer of the liver caused by hepatitis B virus (HBV) are major global health problems. Chronic HBV infection has become more common in Sweden with immigration. The risk of cancer and the...
Eligibility Criteria
Inclusion
- Nucleoside analogue treatment for HBeAg-negative chronic hepatitis B for at least 36 months.
Exclusion
- Liver cirrhosis or liver cancer.
- Co-infection with HCV, HDV or HIV.
- Inability to understand study information and give informed consent
Key Trial Info
Start Date :
November 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2026
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT05328427
Start Date
November 1 2022
End Date
June 30 2026
Last Update
April 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Infectious Diseases Clinic, Sahlgrenska University Hospital
Gothenburg, VGR, Sweden, 41650